Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
melatonin-stimulated mesenchymal stem cell exosomes
- Development stage
- Preclinical
- Lead developer
- Soonchunhyang University
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Topical, Parenteral
01
Overview
Melatonin-stimulated mesenchymal stem cell exosomes (also known as MT-Exo or Exocue) are a cell-free biologic therapy consisting of extracellular vesicles derived from mesenchymal stem cells (MSCs) that have been preconditioned or stimulated with melatonin. This preconditioning process enhances the therapeutic profile of the secreted exosomes by upregulating specific microRNAs (miRNAs) and proteins with potent anti-inflammatory, anti-fibrotic, and antioxidant properties. Preclinical research indicates that these exosomes can modulate the PTEN/AKT signaling pathway to promote M2 macrophage polarization and inhibit pro-fibrotic factors such as TGF-β and pro-inflammatory cytokines like TNF-α. The therapy is primarily being investigated for the treatment of chronic kidney disease (CKD), diabetic wound healing, renal ischemia-reperfusion injury, and hyperoxic lung injury.
- Other names
- melatonin-preconditioned mesenchymal stem cell-derived exosomesmelatonin-treated MSC exosomesmelatonin-stimulated MSC-derived exosomes
02
Targets
AKT (RAC-alpha serine/threonine-protein kinase)TGFB (GARP–latent transforming growth factor beta 1 complex)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on melatonin-stimulated mesenchymal stem cell exosomes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on melatonin-stimulated mesenchymal stem cell exosomes.